Investigators from the University of Pennsylvania have presented data regarding the relationship of angiopoietin-2 (ANG2) and its prognostic impact on traumatic brain injury (TBI). The ANG2 plasmatic levels were measured in patients with TBI (n=362), orthopedic injury controls (n=89) and healthy controls (n=64).

At the recent European Society of Clinical Microbiology and Infectious Diseases (ESCMID) meeting in Vienna, Longhorn Vaccines & Diagnostics LLC presented data on the neutralizing antibody responses of LHNVD-202, an unconjugated composite peptide vaccine.

Biohaven Pharmaceuticals Inc. has presented preclinical data on their novel bispecific degrader BHV-1310 for the potential treatment of autoimmune disorders. To date, about 10% of the global population is affected by autoimmune diseases. IgG-lowering agents have suboptimal pharmacology and pharmacodynamic effects and have safety and tolerability challenges.

Researchers from Tridem Bioscience GmbH & Co. KG provided details on the development of TRB-001, an anti-α-synuclein construct consisting of a B-cell epitope derived from human α-synuclein (SNCA), conjugated to CRM197 and C-type lectin (CLEC) β-glucan.

Researchers from AC Immune SA recently presented the discovery of ACI-21018, a novel α-synuclein aggregation inhibitor developed using AC Immune’s proprietary Morphomer platform.

Neurizon Therapeutics Ltd. has presented preclinical data on their compound NUZ-001 for the potential treatment of neurological disorders.

The specific tau isoforms, such as 3-repeat (3R) and 4-repeat (4R) isoforms, and the distinct conformational strains that misfolded tau can adopt are determinants of the molecular and clinical heterogeneity observed across tauopathies.